This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Astex Pharmaceuticals Announces Initiation Of SGI-110 Phase 2 Trial In Advanced Hepatocellular Carcinoma (HCC) Patients

DUBLIN, Calif., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated a Phase 2, open-label, single-arm, non-randomized clinical trial, evaluating SGI-110 in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with Nexavar (sorafenib).

Advanced Hepatocellular Carcinoma (HCC) is a disease with a very high unmet medical need and patients who do not respond to the frontline standard of care, sorafenib, have few therapeutic options. The Phase 2 study is based on preclinical work showing that SGI-110 is effective in inducing global DNA and gene specific hypomethylation, thus enabling the re-expression of tumor suppressor genes in HCC cell lines ( Jueliger, S. 2012, November. Poster presentation, EORTC-NCI-AACR, Dublin, Ireland).

"There is a high unmet need for therapies for advanced HCC patients who have failed sorafenib treatment," said Mohammad Azab, MD, chief medical officer. "We are pleased to initiate this study which expands the investigational breadth of our development program for SGI-110 to include HCC in addition to the ongoing studies in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and ovarian cancer."

About the Study

The study uses a Simon's 2-stage design. Part A would enroll 15 patients in Stage 1 who will be evaluated for safety, disease control, and for methylation status of certain tumor suppressor genes known to be involved in HCC. If Part A is successful, Part B will enroll 31 additional patients in Stage 2. The primary endpoint of the study is disease control rate (DCR) at 16 weeks, defined as percentage of patients who achieve a best clinical response of complete or partial response, or stable disease at that time. Secondary endpoints of the study include the incidence and severity of adverse events, global DNA methylation levels, methylation status of selected tumor suppressor genes in tumor tissue, progression-free survival and overall survival.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,046.04 -185.98 -1.02%
S&P 500 2,105.81 -20.25 -0.95%
NASDAQ 5,035.4490 -53.9130 -1.06%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs